Source:http://linkedlifedata.com/resource/pubmed/id/16884361
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2006-8-3
|
| pubmed:abstractText |
The molecular etiology of epithelial ovarian cancer remains unclear. Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers. The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum. Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples. Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls). Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01). Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively). Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease. Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis. Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CA-125 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1048-891X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1529-35
|
| pubmed:meshHeading |
pubmed-meshheading:16884361-Adenocarcinoma, Clear Cell,
pubmed-meshheading:16884361-Adenocarcinoma, Mucinous,
pubmed-meshheading:16884361-CA-125 Antigen,
pubmed-meshheading:16884361-Case-Control Studies,
pubmed-meshheading:16884361-Cystadenocarcinoma, Serous,
pubmed-meshheading:16884361-Endometrial Neoplasms,
pubmed-meshheading:16884361-Female,
pubmed-meshheading:16884361-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16884361-Humans,
pubmed-meshheading:16884361-Immunoenzyme Techniques,
pubmed-meshheading:16884361-Insulin-Like Growth Factor Binding Protein 2,
pubmed-meshheading:16884361-Neoplasm Staging,
pubmed-meshheading:16884361-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:16884361-Ovarian Cysts,
pubmed-meshheading:16884361-Ovarian Neoplasms,
pubmed-meshheading:16884361-Ovary,
pubmed-meshheading:16884361-Precancerous Conditions,
pubmed-meshheading:16884361-Preoperative Care,
pubmed-meshheading:16884361-RNA, Messenger,
pubmed-meshheading:16884361-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16884361-Tumor Markers, Biological
|
| pubmed:articleTitle |
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
|
| pubmed:affiliation |
H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, 33612, USA. lancasjm@moffitt.usf.edu
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|